Entrada Therapeutics Inc (TRDA)

$12.69 -0.29 (-2.23%)
Market Cap 485.82M
Revenue (ttm) 25.42M
Net Income (ttm) -143.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -565.50%
Debt to Equity Ratio 0.00
Volume 137,200
Avg Vol 232,886
Day's Range N/A - N/A
Shares Out 38.28M
Stochastic %K 63%
Beta -0.12
Analysts Strong Sell
Price Target $20.00

Company Profile

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 520 9158
Address:
One Design Center Place, Suite 17- 500, Boston, United States
VintageVibes
VintageVibes Mar. 9 at 5:32 AM
$TRDA Analyst Sentiment: Strong Buy. Consensus price targets average around $20.00, suggesting a potential 60% upside.
1 · Reply
outlawinvestor1
outlawinvestor1 Mar. 7 at 7:06 AM
$TRDA great ride so far and guidance in '26 is much welcomed.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 6 at 12:30 PM
$TRDA Q4 '25 Earnings Results & Recap Entrada Therapeutics Inc. expects cash, cash equivalents, and marketable securities of $295.7 million as of December 31, 2025, to fund operations into Q3 2027. The company anticipates progressing ENTR-601-44 and ENTR-601-45 clinical trials, with EU filing for ENTR-601-50 and regulatory submissions for ENTR-601-51 in 2026.
0 · Reply
kubota2323
kubota2323 Feb. 26 at 3:25 PM
$TRDA nstitutional Ownership Managers Funds BAKER BROS. ADVISORS LP 13.27% 5AM Venture Management, LLC 10.61% BlackRock, Inc. 5.62% TCG Crossover Management, LLC 5.46% VANGUARD GROUP INC 4.27% WELLINGTON MANAGEMENT GROUP LLP 2.73% StepStone Group LP 1.99% GEODE CAPITAL MANAGEMENT, LLC 1.67% STATE STREET CORP 1.33% MILLENNIUM MANAGEMENT LLC 1.30%
1 · Reply
DarkVantage
DarkVantage Feb. 18 at 9:01 AM
$TRDA Development-stage biotech where trial readouts are the sole driver; price action will front-run data long before fundamentals change.
0 · Reply
TheTradeXchange
TheTradeXchange Feb. 17 at 12:02 PM
$TRDA - Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 12:21 PM
$TRDA RSI: 43.44, MACD: 0.0810 Vol: 0.48, MA20: 11.07, MA50: 10.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
ShelleyGardner428
ShelleyGardner428 Feb. 11 at 5:16 PM
$TRDA Entrada Therapeutics; biotech (Duchenne MD); early-stage; platform; partnered; binary catalysts.
0 · Reply
buyandsold
buyandsold Jan. 28 at 6:18 PM
$TRDA $CYTK green today deserves a rocket ship emoji
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 7:31 PM
$TRDA RSI: 56.77, MACD: 0.3150 Vol: 0.51, MA20: 10.60, MA50: 10.30 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on TRDA
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 2, 2026, 4:30 PM EST - 13 days ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:00 AM EST - 18 days ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

Feb 17, 2026, 7:00 AM EST - 27 days ago

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

Entrada Therapeutics to Present at Upcoming Investor Conferences

Feb 4, 2026, 7:00 AM EST - 5 weeks ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 15, 2026, 12:45 AM EST - 2 months ago

Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Jan 8, 2026, 7:00 AM EST - 2 months ago

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 17, 2025, 7:00 AM EST - 3 months ago

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts

Nov 17, 2025, 9:30 AM EST - 4 months ago

Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 Readouts

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 4 months ago

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Entrada Therapeutics, Inc. - Special Call

Sep 25, 2025, 2:57 PM EDT - 6 months ago

Entrada Therapeutics, Inc. - Special Call

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Sep 5, 2025, 7:00 AM EDT - 6 months ago

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 7 months ago

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Jun 3, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 11 months ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 24, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Feb 19, 2025, 11:31 AM EST - 1 year ago

Entrada Therapeutics: Cash-Rich Innovator With Asymmetric Upside

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Feb 3, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Jan 30, 2025, 4:05 PM EST - 1 year ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 17, 2024, 8:30 AM EDT - 1 year ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 7:15 AM EDT - 1 year ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 24, 2024, 6:00 AM EDT - 1 year ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 16, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Entrada Therapeutics Reports First Quarter 2024 Financial Results

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Nov 22, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Entrada Therapeutics: Early Stage But Interesting

Aug 3, 2023, 6:39 PM EDT - 2 years ago

Entrada Therapeutics: Early Stage But Interesting

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Entrada Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Apr 4, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 29, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Dec 19, 2022, 4:30 PM EST - 3 years ago

Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy

Entrada Therapeutics shares jump on collaboration with Vertex

Dec 8, 2022, 8:24 AM EST - 3 years ago

Entrada Therapeutics shares jump on collaboration with Vertex

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

Dec 8, 2022, 7:00 AM EST - 3 years ago

Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)

VRTX

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

Nov 7, 2022, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Third Quarter 2022 Financial Results

VintageVibes
VintageVibes Mar. 9 at 5:32 AM
$TRDA Analyst Sentiment: Strong Buy. Consensus price targets average around $20.00, suggesting a potential 60% upside.
1 · Reply
outlawinvestor1
outlawinvestor1 Mar. 7 at 7:06 AM
$TRDA great ride so far and guidance in '26 is much welcomed.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 6 at 12:30 PM
$TRDA Q4 '25 Earnings Results & Recap Entrada Therapeutics Inc. expects cash, cash equivalents, and marketable securities of $295.7 million as of December 31, 2025, to fund operations into Q3 2027. The company anticipates progressing ENTR-601-44 and ENTR-601-45 clinical trials, with EU filing for ENTR-601-50 and regulatory submissions for ENTR-601-51 in 2026.
0 · Reply
kubota2323
kubota2323 Feb. 26 at 3:25 PM
$TRDA nstitutional Ownership Managers Funds BAKER BROS. ADVISORS LP 13.27% 5AM Venture Management, LLC 10.61% BlackRock, Inc. 5.62% TCG Crossover Management, LLC 5.46% VANGUARD GROUP INC 4.27% WELLINGTON MANAGEMENT GROUP LLP 2.73% StepStone Group LP 1.99% GEODE CAPITAL MANAGEMENT, LLC 1.67% STATE STREET CORP 1.33% MILLENNIUM MANAGEMENT LLC 1.30%
1 · Reply
DarkVantage
DarkVantage Feb. 18 at 9:01 AM
$TRDA Development-stage biotech where trial readouts are the sole driver; price action will front-run data long before fundamentals change.
0 · Reply
TheTradeXchange
TheTradeXchange Feb. 17 at 12:02 PM
$TRDA - Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 12 at 12:21 PM
$TRDA RSI: 43.44, MACD: 0.0810 Vol: 0.48, MA20: 11.07, MA50: 10.73 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
1 · Reply
ShelleyGardner428
ShelleyGardner428 Feb. 11 at 5:16 PM
$TRDA Entrada Therapeutics; biotech (Duchenne MD); early-stage; platform; partnered; binary catalysts.
0 · Reply
buyandsold
buyandsold Jan. 28 at 6:18 PM
$TRDA $CYTK green today deserves a rocket ship emoji
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 26 at 7:31 PM
$TRDA RSI: 56.77, MACD: 0.3150 Vol: 0.51, MA20: 10.60, MA50: 10.30 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
kubota2323
kubota2323 Jan. 22 at 3:14 PM
$TRDA added/adding
0 · Reply
ppl_first
ppl_first Jan. 21 at 8:00 PM
$TRDA Platform with high-quality human data and strategic partnerships. Valuation reflects platform skepticism, not asset failure; commercial clock not yet applicable.
0 · Reply
buyandsold
buyandsold Jan. 17 at 6:39 PM
$TRDA the last 3 months have seen 75% gains during a period of no news no catalysts. The future is bright according to the buyers.
0 · Reply
buyandsold
buyandsold Jan. 9 at 8:18 PM
$TRDA need to reclaim 11. I will sell at 50
3 · Reply
ppl_first
ppl_first Jan. 7 at 11:25 PM
$TRDA picked up more today at 9.90
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 29 at 10:57 AM
$TRDA RSI: 51.47, MACD: 0.5017 Vol: 0.44, MA20: 10.62, MA50: 8.84 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MastMeteorology
MastMeteorology Dec. 26 at 5:40 PM
$TRDA Price action signals that reliability now matters more than headline momentum. Governance alignment should reduce uncertainty over time. Risk compresses once delivery patterns become predictable. Upside remains tied to tangible progress, not assumptions.
0 · Reply
ppl_first
ppl_first Dec. 24 at 3:56 PM
$TRDA is a pre-binary upswing candidate because it has catalysts approaching, cash runway, and future binary decisions, albeit not near-term. Great time to accumulate the dips.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 15 at 11:20 AM
$TRDA Share Price: $11.09 Contract Selected: Jun 18, 2026 $10 Calls Buy Zone: $0.72 – $0.89 Target Zone: $1.29 – $1.57 Potential Upside: 68% ROI Time to Expiration: 184 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
MrEsKurr
MrEsKurr Dec. 9 at 12:27 AM
$TRDA not sleeping on this one it looks tidy and ready to go.
1 · Reply